Nuwellis expands Aquadex strategy into broader extracorporeal therapy platform

Reuters2026/08/04 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nuwellis launched a development program to expand its Aquadex SmartFlow into a broader extracorporeal therapy platform for critical care.
Work targets higher blood-flow rates, wider operating pressure ranges, broader compatibility with advanced extracorporeal therapies.
Strategy aims to expand the long-term market beyond fluid overload into blood purification, immunomodulation, extracorporeal life support.
Platform could support collaborations with developers of blood purification therapies using Nuwellis’ precise fluid-management technology.
Initiative remains at research stage, not FDA cleared or available for commercial sale or clinical use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040830PRIMZONEFULLFEED9802801) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nuwellis expands Aquadex strategy into broader extracorporeal therapy platform

You may also like

Crypto prices